Hyal-Joint (Hyaluronic Acid from Chicken Comb)

Hyal-Joint is a patented oral hyaluronic acid derived from chicken sternal cartilage and combs, standardized for high-molecular-weight hyaluronan chains. It works primarily by restoring synovial fluid viscosity and stimulating endogenous hyaluronan synthesis via CD44 receptor signaling in synoviocytes.

Origin & History

Hyal-Joint is a branded natural extract derived from chicken (rooster or hen) combs, standardized to contain 60% hyaluronic acid along with glycosaminoglycans (20%) and partially hydrolyzed proteins. The extraction process involves soaking dehydrated combs in distilled water, removing proteins with sodium chloride and chloroform, followed by ethanol precipitation and dehydration.

Historical & Cultural Context

Rooster combs have been consumed in Europe as part of traditional dishes including soups, stews, and high-cuisine recipes. However, no formal traditional medicine systems or historical documentation for joint health applications were found.

Health Benefits

• Improved knee pain in osteoarthritis patients - preliminary evidence from one small RCT (n=20)
• Enhanced joint stiffness reduction - based on WOMAC scores in pilot study
• Better physical function scores - shown in 8-week trial versus placebo
• Improved quality of life markers in joint health - limited to one small clinical trial
• Potential joint lubrication support through hyaluronic acid content - theoretical based on mechanism

How It Works

Hyal-Joint delivers high-molecular-weight hyaluronic acid (HA) that binds CD44 and RHAMM receptors on synoviocytes and chondrocytes, suppressing NF-κB-mediated pro-inflammatory cytokine release including IL-1β and TNF-α. Oral HA fragments are absorbed in the small intestine and transported to synovial tissue, where they upregulate endogenous hyaluronan synthase 2 (HAS2) expression, increasing synovial fluid HA concentration and restoring viscoelastic lubrication. Additionally, HA binding to TLR4 receptor competitors may inhibit matrix metalloproteinase (MMP-3 and MMP-13) activity, reducing cartilage matrix degradation.

Scientific Research

A pilot randomized double-blind placebo-controlled trial (PMID: 18208600) tested Hyal-Joint in 20 adults with knee osteoarthritis at 80 mg/day for 8 weeks, showing improvements in WOMAC pain, stiffness, and physical function scores versus placebo. However, the small sample size limits conclusions and no additional RCTs or meta-analyses specific to Hyal-Joint were identified.

Clinical Summary

The primary human evidence for Hyal-Joint consists of a small randomized controlled trial (n=20) comparing 80 mg/day oral HA to placebo over 8 weeks, which reported statistically significant reductions in WOMAC pain and stiffness subscores. Physical function composite scores also improved versus placebo in this pilot study, though the sample size limits generalizability. A subset analysis noted improved quality-of-life markers, but no large-scale Phase III trials have been published specifically for the Hyal-Joint branded ingredient. Overall, evidence is preliminary and promising but insufficient to draw definitive clinical conclusions without replication in larger, longer-duration trials.

Nutritional Profile

Hyal-Joint is a concentrated hyaluronic acid (HA) extract derived from chicken sternal cartilage/comb, standardized to contain approximately 60% hyaluronic acid by weight. Primary bioactive compound is high-molecular-weight hyaluronic acid (HMW-HA), with molecular weight typically ranging from 1,500,000 to 2,500,000 Da (1.5–2.5 MDa), which is relevant to its viscosupplement and joint lubrication properties. Typical oral supplemental doses range from 80–200 mg/day of the extract, delivering approximately 48–120 mg of actual HA per serving. Protein content is minimal (<5% by dry weight), largely residual from the extraction process. Carbohydrate content is negligible. Fat content is near zero. No meaningful fiber, vitamin, or mineral contributions are present at supplemental doses. Bioavailability note: Oral HA absorption is a subject of ongoing research; low-molecular-weight fragments (generated via GI enzymatic degradation) and intact oligosaccharide chains may be partially absorbed via intestinal epithelium and transported to synovial tissue, though absolute bioavailability of HMW-HA is estimated at <10%. Some studies suggest HA can reach synovial fluid at detectable concentrations after oral dosing. The chicken comb source is noted to yield a more native, less processed HA compared to microbial fermentation sources, potentially preserving molecular weight integrity. No significant allergen-free certification is implied; poultry-derived source warrants caution in avian protein-sensitive individuals.

Preparation & Dosage

The clinically studied dosage is 80 mg/day of Hyal-Joint powder (providing approximately 48 mg hyaluronic acid) taken orally for 8 weeks. No other dosage ranges or forms have been studied. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Glucosamine, Chondroitin, MSM, Collagen Type II, Boswellia

Safety & Interactions

Hyal-Joint is generally well tolerated at doses of 80–200 mg/day, with no serious adverse events reported in published pilot trials; mild gastrointestinal discomfort has been noted in isolated cases. Because HA is derived from chicken combs, individuals with poultry or egg allergies should exercise caution and consult a physician before use. No clinically significant drug interactions have been formally documented, though theoretical caution is warranted with anticoagulants such as warfarin, as high-dose HA may mildly influence platelet aggregation pathways. Safety data in pregnant or breastfeeding women is absent, and use during pregnancy is not recommended without medical supervision.